IDORSIA AG
Idorsia Ltd, a biopharmaceutical company, discovers, develops, and commercializes drugs for unmet medical needs in Switzerland. The company has a clinical development pipeline that cover various therapeutic areas, including CNS, cardiovascular, and immunological disorders, as well as orphan diseases. Idorsia Ltd has a collaboration agreement with Janssen Biotech Inc. to jointly develop and commer… Read more
IDORSIA AG (19T) - Net Assets
Latest net assets as of June 2025: €-1.14 Billion EUR
Based on the latest financial reports, IDORSIA AG (19T) has net assets worth €-1.14 Billion EUR as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€498.01 Million) and total liabilities (€1.64 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €-1.14 Billion |
| % of Total Assets | -229.22% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
IDORSIA AG - Net Assets Trend (2021–2024)
This chart illustrates how IDORSIA AG's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for IDORSIA AG (2021–2024)
The table below shows the annual net assets of IDORSIA AG from 2021 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | €-1.21 Billion | -25.13% |
| 2023-12-31 | €-968.72 Million | -46.56% |
| 2022-12-31 | €-660.96 Million | -734.29% |
| 2021-12-31 | €104.20 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to IDORSIA AG's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 142469700000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €2.19 Billion | % |
| Total Equity | €-1.21 Billion | 100.00% |
IDORSIA AG Competitors by Market Cap
The table below lists competitors of IDORSIA AG ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
MultiChoice Group Ltd
PINK:MCOIF
|
$532.56 Million |
|
Salzgitter AG
PINK:SZGPF
|
$532.82 Million |
|
Hunan Aerospace Huanyu Communication Technology Co. Ltd. A
SHG:688523
|
$532.84 Million |
|
Zhuhai Enpower Electric Co Ltd
SHE:300681
|
$532.89 Million |
|
Ethan Allen Interiors Inc
NYSE:ETD
|
$532.41 Million |
|
Quanta Storage
TWO:6188
|
$532.29 Million |
|
Xiamen Jihong Package Technology Ltd
SHE:002803
|
$532.29 Million |
|
Gas Malaysia Bhd
KLSE:5209
|
$532.26 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in IDORSIA AG's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from -968,718,000 to -1,212,145,000, a change of -243,427,000.
- Net loss of 263,757,000 reduced equity.
- Share repurchases of 80,000 reduced equity.
- Other factors increased equity by 20,410,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-263.76 Million | -21.76% |
| Share Repurchases | €80.00K | -0.01% |
| Other Changes | €20.41 Million | +1.68% |
| Total Change | €- | % |
Book Value vs Market Value Analysis
This analysis compares IDORSIA AG's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | €0.59 | €3.18 | x |
| 2022-12-31 | €-3.72 | €3.18 | x |
| 2023-12-31 | €-5.42 | €3.18 | x |
| 2024-12-31 | €-6.43 | €3.18 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently IDORSIA AG utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -234.43%
- • Asset Turnover: 0.22x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-152.25%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | -608.99% | -1795.23% | 0.02x | 14.23x | €-645.02 Million |
| 2022 | 0.00% | -852.60% | 0.11x | 0.00x | €-761.80 Million |
| 2023 | 0.00% | -195.50% | 0.30x | 0.00x | €-201.05 Million |
| 2024 | 0.00% | -234.43% | 0.22x | 0.00x | €-142.54 Million |
Industry Comparison
This section compares IDORSIA AG's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,542,173,198
- Average return on equity (ROE) among peers: -27.21%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| IDORSIA AG (19T) | €-1.14 Billion | -608.99% | N/A | $532.51 Million |
| 09R (09R) | $-3.01 Million | 0.00% | 0.00x | $11.12 Million |
| 1S90 (1S90) | $-44.86 Million | 0.00% | 0.00x | $51.72 Million |
| Strategic Partners A/S (1TB0) | $14.24 Million | -182.90% | 0.36x | $1.31 Million |
| 25K0 (25K0) | $-16.66 Million | 0.00% | 0.00x | $102.39 Million |
| 2BO (2BO) | $-37.78 Million | 0.00% | 0.00x | $6.23 Million |
| Intervacc AB (publ) (2E9) | $237.93 Million | -43.23% | 0.09x | $3.46 Million |
| 2F5 (2F5) | $-4.57 Million | 0.00% | 0.00x | $2.14 Million |
| 2H0 (2H0) | $14.92 Million | -17.30% | 0.56x | $9.25 Million |
| GNI Group Ltd (3G6) | $13.72 Billion | -1.46% | 0.26x | $772.60 Million |